BioSpace News Archive

Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced it has received more than $136,000 from Orveon Global.

Biovica International The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2022, and the Chairman of the Board.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2022.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023.

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2022.

OKYO Pharma Limited, a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares at a public offering price of $1.50 per ADS.

ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of renal and inflammatory diseases with high unmet medical needs, announced the grant of inducement equity awards to two new employees.

Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid” or the “Company”) today provided a business update for the Company and presented financial results for the year ended December 31, 2022.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced the Company has entered into a new agreement with holders of its convertible notes that provides for a 21-day moratorium on conversion of those convertible notes.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”) announced today that its partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) reported positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN).